Amal Cheurfa

[Benlazar S M A @smbenlazar]

management of R/R DLBCL : UK guidelines #lymsm

[Benlazar S M A @smbenlazar]

Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management https://t.co/mYJOVVKCVG #MDS2026

[Benlazar S M A @smbenlazar]

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma https://t.co/DvnBM7arDL #lymsm

[Benlazar S M A @smbenlazar]

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant https://t.co/LS0V44lDzN

[Benlazar S M A @smbenlazar]

Inotuzumab ozogamicin in paediatric very high risk first
B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial https://t.co/pM2dWxTYGq #ALL #leusm

[Amal Cheurfa @CheurfaAma50694]

@haukma يااااااارب